**Supplemental Table 1. Associations of *APOE* alleles with neuropathological findings at autopsy.**

|  |  |
| --- | --- |
|  | **NEUROPATHOLOGICAL OUTCOME MEASURE** |
| **BRAAK NFT stage***(III/IV vs 0/I/II)* | **CERAD NP score***(moderate vs none/sparse)* | **CAA** | **Lewy bodies***(present vs none)* | **Hippocampal sclerosis***(present vs none)* | **Arteriolosclerosis***(mild vs none, or moderate vs mild, or severe vs moderate)* |
| *(mild vs none)* | *(moderate vs mild)* | *(severe vs moderate)* |
| Log[OR (95%CI)] | Log[OR (95%CI)] | Log[OR (95%CI)] | Log[OR (95%CI)] | Log[OR (95%CI)] | Log[OR (95%CI)] | Log[OR (95%CI)] | Log[OR (95%CI)] |
| **Presence of *APOE*2 allele** | **-0.05****(-0.13, -0.03)** | **-0.65****(-1.09, -0.24)** | -0.09(-0.32, 0.13) | -0.09(-0.32, 0.13) | -0.09(-0.32, 0.13) | -0.02(-0.09, 0.06) | 0.004(-0.04, 0.05) | 0.02(-0.18, 0.22) |
| **Presence of *APOE*4 allele** | **0.21****(0.15, 0.28)** | **0.78****(0.49, 1.07)** | **0.59****(0.42, 0.75)** | **0.59****(0.42, 0.75)** | **0.59****(0.42, 0.75)** | **0.13****(0.07, 0.19)** | 0.005(-0.03, 0.04) | -0.05(-0.22, 0.11) |
| **Presence of 1 *APOE*4 allele** | **0.19****(0.12, 0.26)** | **0.76****(0.46, 1.06)** | **0.74****(0.39, 1.10)** | 0.33(-0.12, 0.78) | -0.13(-0.93, 0.67) | **0.14****(0.07, 0.20)** | 0.006(-0.03, 0.05) | -0.11(-0.28, 0.07) |
| **Presence of 2 *APOE*4 alleles** | **0.41****(0.24, 0.59)** | **0.94****(0.17, 1.70)** | **1.65****(1.20, 2.11)** | **1.65****(1.20, 2.11)** | **1.65****(1.20, 2.11)** | 0.06(-0.10, 0.22) | -0.001(-0.10, 0.10) | 0.45(-0.01, 0.91) |

All analyses were adjusted by age at death, sex, and education. Braak NFT stage and CAA analyses were also adjusted by CERAD NP score. Number of subjects in *APOE*ε2, *APOE*ε3/ε3, and *APOE*ε4 groups are 153, 651, and 273, respectively. Number of subjects with one and two *APOE*ε4 alleles are 244 and 29, respectively. Abbreviations: CAA = cerebral amyloid angiopathy; CI = confidence interval; NFT = neurofibrillary tangle; NP = neuritic plaque; OR = odds ratio.